Clinical case of pathological complete response of gastric cancer after one cycle of neoadjuvant chemotherapy with fot regimen

Background. Gastric cancer is the 5th most common cancer and the 3rd leading cause of cancer death globally. In Russia, gastric cancer is the 2-nd leading cause of death (10.7 %). Surgery in combination with perioperative/adjuvant chemotherapy is the standard treatment for locally advanced gastric c...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	V. Yu. Skoropad [verfasserIn] D. D. Kudriavtsev [verfasserIn] V. N. Shitareva [verfasserIn] E. S. Zhavoronkovа [verfasserIn]

Format:	E-Artikel
Sprache:	Russisch

Erschienen:	2023

Schlagwörter:	рак желудка периоперационная химиотерапия flot хирургическое лечение гастрэктомия лечебный патоморфоз динамическое наблюдение

Übergeordnetes Werk:	In: Сибирский онкологический журнал - Russian Academy of Sciences, Tomsk National Research Medical Center, 2017, 21(2023), 6, Seite 164-169
Übergeordnetes Werk:	volume:21 ; year:2023 ; number:6 ; pages:164-169

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc Journal toc

DOI / URN:	10.21294/1814-4861-2022-21-6-164-169

Katalog-ID:	DOAJ088670007

Internformat


LEADER	01000naa a22002652 4500
001	DOAJ088670007
003	DE-627
005	20230410120511.0
007	cr uuu---uuuuu
008	230410s2023 xx \|\|\|\|\|o 00\| \|\|rus c
024	7		\|a 10.21294/1814-4861-2022-21-6-164-169 \|2 doi
035			\|a (DE-627)DOAJ088670007
035			\|a (DE-599)DOAJ03836cccc4a54d439514afd374b1264b
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a rus
050		0	\|a RC254-282
100	0		\|a V. Yu. Skoropad \|e verfasserin \|4 aut
245	1	0	\|a Clinical case of pathological complete response of gastric cancer after one cycle of neoadjuvant chemotherapy with fot regimen
264		1	\|c 2023
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Background. Gastric cancer is the 5th most common cancer and the 3rd leading cause of cancer death globally. In Russia, gastric cancer is the 2-nd leading cause of death (10.7 %). Surgery in combination with perioperative/adjuvant chemotherapy is the standard treatment for locally advanced gastric cancer. Four cycles of neoadjuvant chemotherapy and 4 cycles of adjuvant chemotherapy with the FLOT regimen is the most widely used treatment modality. The basis for the widespread use of this chemotherapy regimen was the results of a large randomized FLOT4 trial, according to which the perioperative FLOT regimen showed greater efficacy compared to the ECF regimen.The aim of the study was to demonstrate the feasibility of achieving patholopgical complete response and long-term remission after one course of neoadjuvant chemotherapy with FLOT regimen in a patient with locally advanced gastric cancer.Case description. A 69-year-old patient presented to A. Tsyb Medical Radiological Research Centre with complaints of general weakness, moderate epigastric pain for 2 months. The examination revealed stage T3N0M0 IIA gastric cancer. The patient received one cycle of neoadjuvant chemotherapy with the FLOT regimen. Given the fact, that the patient developed massive bleeding from the tumor, it was decided to stop neoadjuvant treatment. Subtotal gastrectomy with D2 lymph node dissection was performed. Histological examination of the surgical specimen revealed pathological complete response (grade 1a according to the classification of K.Becker et al., 2003). The patient is alive with no signs of disease progression for more than 36 months after starting the treatment.Conclusion. This clinical case demonstrated personalized approach to the treatment of patients with locally advanced gastric cancer. Pathological complete response was achieved after one cycle of neoadjuvant chemotherapy.
650		4	\|a рак желудка
650		4	\|a периоперационная химиотерапия flot
650		4	\|a хирургическое лечение
650		4	\|a гастрэктомия
650		4	\|a лечебный патоморфоз
650		4	\|a динамическое наблюдение
653		0	\|a Neoplasms. Tumors. Oncology. Including cancer and carcinogens
700	0		\|a D. D. Kudriavtsev \|e verfasserin \|4 aut
700	0		\|a V. N. Shitareva \|e verfasserin \|4 aut
700	0		\|a E. S. Zhavoronkovа \|e verfasserin \|4 aut
773	0	8	\|i In \|t Сибирский онкологический журнал \|d Russian Academy of Sciences, Tomsk National Research Medical Center, 2017 \|g 21(2023), 6, Seite 164-169 \|w (DE-627)731335074 \|w (DE-600)2693095-X \|x 23123168 \|7 nnns
773	1	8	\|g volume:21 \|g year:2023 \|g number:6 \|g pages:164-169
856	4	0	\|u https://doi.org/10.21294/1814-4861-2022-21-6-164-169 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/03836cccc4a54d439514afd374b1264b \|z kostenfrei
856	4	0	\|u https://www.siboncoj.ru/jour/article/view/2388 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1814-4861 \|y Journal toc \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2312-3168 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 21 \|j 2023 \|e 6 \|h 164-169

Indexfelder

author_variant	v y s vys d d k ddk v n s vns e s z esz
matchkey_str	article:23123168:2023----::lnclaefahlgclopeeepnefaticneatrnccefeajv
hierarchy_sort_str	2023
callnumber-subject-code	RC
publishDate	2023
allfields	10.21294/1814-4861-2022-21-6-164-169 doi (DE-627)DOAJ088670007 (DE-599)DOAJ03836cccc4a54d439514afd374b1264b DE-627 ger DE-627 rakwb rus RC254-282 V. Yu. Skoropad verfasserin aut Clinical case of pathological complete response of gastric cancer after one cycle of neoadjuvant chemotherapy with fot regimen 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background. Gastric cancer is the 5th most common cancer and the 3rd leading cause of cancer death globally. In Russia, gastric cancer is the 2-nd leading cause of death (10.7 %). Surgery in combination with perioperative/adjuvant chemotherapy is the standard treatment for locally advanced gastric cancer. Four cycles of neoadjuvant chemotherapy and 4 cycles of adjuvant chemotherapy with the FLOT regimen is the most widely used treatment modality. The basis for the widespread use of this chemotherapy regimen was the results of a large randomized FLOT4 trial, according to which the perioperative FLOT regimen showed greater efficacy compared to the ECF regimen.The aim of the study was to demonstrate the feasibility of achieving patholopgical complete response and long-term remission after one course of neoadjuvant chemotherapy with FLOT regimen in a patient with locally advanced gastric cancer.Case description. A 69-year-old patient presented to A. Tsyb Medical Radiological Research Centre with complaints of general weakness, moderate epigastric pain for 2 months. The examination revealed stage T3N0M0 IIA gastric cancer. The patient received one cycle of neoadjuvant chemotherapy with the FLOT regimen. Given the fact, that the patient developed massive bleeding from the tumor, it was decided to stop neoadjuvant treatment. Subtotal gastrectomy with D2 lymph node dissection was performed. Histological examination of the surgical specimen revealed pathological complete response (grade 1a according to the classification of K.Becker et al., 2003). The patient is alive with no signs of disease progression for more than 36 months after starting the treatment.Conclusion. This clinical case demonstrated personalized approach to the treatment of patients with locally advanced gastric cancer. Pathological complete response was achieved after one cycle of neoadjuvant chemotherapy. рак желудка периоперационная химиотерапия flot хирургическое лечение гастрэктомия лечебный патоморфоз динамическое наблюдение Neoplasms. Tumors. Oncology. Including cancer and carcinogens D. D. Kudriavtsev verfasserin aut V. N. Shitareva verfasserin aut E. S. Zhavoronkovа verfasserin aut In Сибирский онкологический журнал Russian Academy of Sciences, Tomsk National Research Medical Center, 2017 21(2023), 6, Seite 164-169 (DE-627)731335074 (DE-600)2693095-X 23123168 nnns volume:21 year:2023 number:6 pages:164-169 https://doi.org/10.21294/1814-4861-2022-21-6-164-169 kostenfrei https://doaj.org/article/03836cccc4a54d439514afd374b1264b kostenfrei https://www.siboncoj.ru/jour/article/view/2388 kostenfrei https://doaj.org/toc/1814-4861 Journal toc kostenfrei https://doaj.org/toc/2312-3168 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 21 2023 6 164-169
spelling	10.21294/1814-4861-2022-21-6-164-169 doi (DE-627)DOAJ088670007 (DE-599)DOAJ03836cccc4a54d439514afd374b1264b DE-627 ger DE-627 rakwb rus RC254-282 V. Yu. Skoropad verfasserin aut Clinical case of pathological complete response of gastric cancer after one cycle of neoadjuvant chemotherapy with fot regimen 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background. Gastric cancer is the 5th most common cancer and the 3rd leading cause of cancer death globally. In Russia, gastric cancer is the 2-nd leading cause of death (10.7 %). Surgery in combination with perioperative/adjuvant chemotherapy is the standard treatment for locally advanced gastric cancer. Four cycles of neoadjuvant chemotherapy and 4 cycles of adjuvant chemotherapy with the FLOT regimen is the most widely used treatment modality. The basis for the widespread use of this chemotherapy regimen was the results of a large randomized FLOT4 trial, according to which the perioperative FLOT regimen showed greater efficacy compared to the ECF regimen.The aim of the study was to demonstrate the feasibility of achieving patholopgical complete response and long-term remission after one course of neoadjuvant chemotherapy with FLOT regimen in a patient with locally advanced gastric cancer.Case description. A 69-year-old patient presented to A. Tsyb Medical Radiological Research Centre with complaints of general weakness, moderate epigastric pain for 2 months. The examination revealed stage T3N0M0 IIA gastric cancer. The patient received one cycle of neoadjuvant chemotherapy with the FLOT regimen. Given the fact, that the patient developed massive bleeding from the tumor, it was decided to stop neoadjuvant treatment. Subtotal gastrectomy with D2 lymph node dissection was performed. Histological examination of the surgical specimen revealed pathological complete response (grade 1a according to the classification of K.Becker et al., 2003). The patient is alive with no signs of disease progression for more than 36 months after starting the treatment.Conclusion. This clinical case demonstrated personalized approach to the treatment of patients with locally advanced gastric cancer. Pathological complete response was achieved after one cycle of neoadjuvant chemotherapy. рак желудка периоперационная химиотерапия flot хирургическое лечение гастрэктомия лечебный патоморфоз динамическое наблюдение Neoplasms. Tumors. Oncology. Including cancer and carcinogens D. D. Kudriavtsev verfasserin aut V. N. Shitareva verfasserin aut E. S. Zhavoronkovа verfasserin aut In Сибирский онкологический журнал Russian Academy of Sciences, Tomsk National Research Medical Center, 2017 21(2023), 6, Seite 164-169 (DE-627)731335074 (DE-600)2693095-X 23123168 nnns volume:21 year:2023 number:6 pages:164-169 https://doi.org/10.21294/1814-4861-2022-21-6-164-169 kostenfrei https://doaj.org/article/03836cccc4a54d439514afd374b1264b kostenfrei https://www.siboncoj.ru/jour/article/view/2388 kostenfrei https://doaj.org/toc/1814-4861 Journal toc kostenfrei https://doaj.org/toc/2312-3168 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 21 2023 6 164-169
allfields_unstemmed	10.21294/1814-4861-2022-21-6-164-169 doi (DE-627)DOAJ088670007 (DE-599)DOAJ03836cccc4a54d439514afd374b1264b DE-627 ger DE-627 rakwb rus RC254-282 V. Yu. Skoropad verfasserin aut Clinical case of pathological complete response of gastric cancer after one cycle of neoadjuvant chemotherapy with fot regimen 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background. Gastric cancer is the 5th most common cancer and the 3rd leading cause of cancer death globally. In Russia, gastric cancer is the 2-nd leading cause of death (10.7 %). Surgery in combination with perioperative/adjuvant chemotherapy is the standard treatment for locally advanced gastric cancer. Four cycles of neoadjuvant chemotherapy and 4 cycles of adjuvant chemotherapy with the FLOT regimen is the most widely used treatment modality. The basis for the widespread use of this chemotherapy regimen was the results of a large randomized FLOT4 trial, according to which the perioperative FLOT regimen showed greater efficacy compared to the ECF regimen.The aim of the study was to demonstrate the feasibility of achieving patholopgical complete response and long-term remission after one course of neoadjuvant chemotherapy with FLOT regimen in a patient with locally advanced gastric cancer.Case description. A 69-year-old patient presented to A. Tsyb Medical Radiological Research Centre with complaints of general weakness, moderate epigastric pain for 2 months. The examination revealed stage T3N0M0 IIA gastric cancer. The patient received one cycle of neoadjuvant chemotherapy with the FLOT regimen. Given the fact, that the patient developed massive bleeding from the tumor, it was decided to stop neoadjuvant treatment. Subtotal gastrectomy with D2 lymph node dissection was performed. Histological examination of the surgical specimen revealed pathological complete response (grade 1a according to the classification of K.Becker et al., 2003). The patient is alive with no signs of disease progression for more than 36 months after starting the treatment.Conclusion. This clinical case demonstrated personalized approach to the treatment of patients with locally advanced gastric cancer. Pathological complete response was achieved after one cycle of neoadjuvant chemotherapy. рак желудка периоперационная химиотерапия flot хирургическое лечение гастрэктомия лечебный патоморфоз динамическое наблюдение Neoplasms. Tumors. Oncology. Including cancer and carcinogens D. D. Kudriavtsev verfasserin aut V. N. Shitareva verfasserin aut E. S. Zhavoronkovа verfasserin aut In Сибирский онкологический журнал Russian Academy of Sciences, Tomsk National Research Medical Center, 2017 21(2023), 6, Seite 164-169 (DE-627)731335074 (DE-600)2693095-X 23123168 nnns volume:21 year:2023 number:6 pages:164-169 https://doi.org/10.21294/1814-4861-2022-21-6-164-169 kostenfrei https://doaj.org/article/03836cccc4a54d439514afd374b1264b kostenfrei https://www.siboncoj.ru/jour/article/view/2388 kostenfrei https://doaj.org/toc/1814-4861 Journal toc kostenfrei https://doaj.org/toc/2312-3168 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 21 2023 6 164-169
allfieldsGer	10.21294/1814-4861-2022-21-6-164-169 doi (DE-627)DOAJ088670007 (DE-599)DOAJ03836cccc4a54d439514afd374b1264b DE-627 ger DE-627 rakwb rus RC254-282 V. Yu. Skoropad verfasserin aut Clinical case of pathological complete response of gastric cancer after one cycle of neoadjuvant chemotherapy with fot regimen 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background. Gastric cancer is the 5th most common cancer and the 3rd leading cause of cancer death globally. In Russia, gastric cancer is the 2-nd leading cause of death (10.7 %). Surgery in combination with perioperative/adjuvant chemotherapy is the standard treatment for locally advanced gastric cancer. Four cycles of neoadjuvant chemotherapy and 4 cycles of adjuvant chemotherapy with the FLOT regimen is the most widely used treatment modality. The basis for the widespread use of this chemotherapy regimen was the results of a large randomized FLOT4 trial, according to which the perioperative FLOT regimen showed greater efficacy compared to the ECF regimen.The aim of the study was to demonstrate the feasibility of achieving patholopgical complete response and long-term remission after one course of neoadjuvant chemotherapy with FLOT regimen in a patient with locally advanced gastric cancer.Case description. A 69-year-old patient presented to A. Tsyb Medical Radiological Research Centre with complaints of general weakness, moderate epigastric pain for 2 months. The examination revealed stage T3N0M0 IIA gastric cancer. The patient received one cycle of neoadjuvant chemotherapy with the FLOT regimen. Given the fact, that the patient developed massive bleeding from the tumor, it was decided to stop neoadjuvant treatment. Subtotal gastrectomy with D2 lymph node dissection was performed. Histological examination of the surgical specimen revealed pathological complete response (grade 1a according to the classification of K.Becker et al., 2003). The patient is alive with no signs of disease progression for more than 36 months after starting the treatment.Conclusion. This clinical case demonstrated personalized approach to the treatment of patients with locally advanced gastric cancer. Pathological complete response was achieved after one cycle of neoadjuvant chemotherapy. рак желудка периоперационная химиотерапия flot хирургическое лечение гастрэктомия лечебный патоморфоз динамическое наблюдение Neoplasms. Tumors. Oncology. Including cancer and carcinogens D. D. Kudriavtsev verfasserin aut V. N. Shitareva verfasserin aut E. S. Zhavoronkovа verfasserin aut In Сибирский онкологический журнал Russian Academy of Sciences, Tomsk National Research Medical Center, 2017 21(2023), 6, Seite 164-169 (DE-627)731335074 (DE-600)2693095-X 23123168 nnns volume:21 year:2023 number:6 pages:164-169 https://doi.org/10.21294/1814-4861-2022-21-6-164-169 kostenfrei https://doaj.org/article/03836cccc4a54d439514afd374b1264b kostenfrei https://www.siboncoj.ru/jour/article/view/2388 kostenfrei https://doaj.org/toc/1814-4861 Journal toc kostenfrei https://doaj.org/toc/2312-3168 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 21 2023 6 164-169
allfieldsSound	10.21294/1814-4861-2022-21-6-164-169 doi (DE-627)DOAJ088670007 (DE-599)DOAJ03836cccc4a54d439514afd374b1264b DE-627 ger DE-627 rakwb rus RC254-282 V. Yu. Skoropad verfasserin aut Clinical case of pathological complete response of gastric cancer after one cycle of neoadjuvant chemotherapy with fot regimen 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background. Gastric cancer is the 5th most common cancer and the 3rd leading cause of cancer death globally. In Russia, gastric cancer is the 2-nd leading cause of death (10.7 %). Surgery in combination with perioperative/adjuvant chemotherapy is the standard treatment for locally advanced gastric cancer. Four cycles of neoadjuvant chemotherapy and 4 cycles of adjuvant chemotherapy with the FLOT regimen is the most widely used treatment modality. The basis for the widespread use of this chemotherapy regimen was the results of a large randomized FLOT4 trial, according to which the perioperative FLOT regimen showed greater efficacy compared to the ECF regimen.The aim of the study was to demonstrate the feasibility of achieving patholopgical complete response and long-term remission after one course of neoadjuvant chemotherapy with FLOT regimen in a patient with locally advanced gastric cancer.Case description. A 69-year-old patient presented to A. Tsyb Medical Radiological Research Centre with complaints of general weakness, moderate epigastric pain for 2 months. The examination revealed stage T3N0M0 IIA gastric cancer. The patient received one cycle of neoadjuvant chemotherapy with the FLOT regimen. Given the fact, that the patient developed massive bleeding from the tumor, it was decided to stop neoadjuvant treatment. Subtotal gastrectomy with D2 lymph node dissection was performed. Histological examination of the surgical specimen revealed pathological complete response (grade 1a according to the classification of K.Becker et al., 2003). The patient is alive with no signs of disease progression for more than 36 months after starting the treatment.Conclusion. This clinical case demonstrated personalized approach to the treatment of patients with locally advanced gastric cancer. Pathological complete response was achieved after one cycle of neoadjuvant chemotherapy. рак желудка периоперационная химиотерапия flot хирургическое лечение гастрэктомия лечебный патоморфоз динамическое наблюдение Neoplasms. Tumors. Oncology. Including cancer and carcinogens D. D. Kudriavtsev verfasserin aut V. N. Shitareva verfasserin aut E. S. Zhavoronkovа verfasserin aut In Сибирский онкологический журнал Russian Academy of Sciences, Tomsk National Research Medical Center, 2017 21(2023), 6, Seite 164-169 (DE-627)731335074 (DE-600)2693095-X 23123168 nnns volume:21 year:2023 number:6 pages:164-169 https://doi.org/10.21294/1814-4861-2022-21-6-164-169 kostenfrei https://doaj.org/article/03836cccc4a54d439514afd374b1264b kostenfrei https://www.siboncoj.ru/jour/article/view/2388 kostenfrei https://doaj.org/toc/1814-4861 Journal toc kostenfrei https://doaj.org/toc/2312-3168 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 21 2023 6 164-169
language	Russian
source	In Сибирский онкологический журнал 21(2023), 6, Seite 164-169 volume:21 year:2023 number:6 pages:164-169
sourceStr	In Сибирский онкологический журнал 21(2023), 6, Seite 164-169 volume:21 year:2023 number:6 pages:164-169
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	рак желудка периоперационная химиотерапия flot хирургическое лечение гастрэктомия лечебный патоморфоз динамическое наблюдение Neoplasms. Tumors. Oncology. Including cancer and carcinogens
isfreeaccess_bool	true
container_title	Сибирский онкологический журнал
authorswithroles_txt_mv	V. Yu. Skoropad @@aut@@ D. D. Kudriavtsev @@aut@@ V. N. Shitareva @@aut@@ E. S. Zhavoronkovа @@aut@@
publishDateDaySort_date	2023-01-01T00:00:00Z
hierarchy_top_id	731335074
id	DOAJ088670007
language_de	russisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ088670007</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230410120511.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230410s2023 xx \|\|\|\|\|o 00\| \|\|rus c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.21294/1814-4861-2022-21-6-164-169</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ088670007</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ03836cccc4a54d439514afd374b1264b</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">V. Yu. Skoropad</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Clinical case of pathological complete response of gastric cancer after one cycle of neoadjuvant chemotherapy with fot regimen</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background. Gastric cancer is the 5th most common cancer and the 3rd leading cause of cancer death globally. In Russia, gastric cancer is the 2-nd leading cause of death (10.7 %). Surgery in combination with perioperative/adjuvant chemotherapy is the standard treatment for locally advanced gastric cancer. Four cycles of neoadjuvant chemotherapy and 4 cycles of adjuvant chemotherapy with the FLOT regimen is the most widely used treatment modality. The basis for the widespread use of this chemotherapy regimen was the results of a large randomized FLOT4 trial, according to which the perioperative FLOT regimen showed greater efficacy compared to the ECF regimen.The aim of the study was to demonstrate the feasibility of achieving patholopgical complete response and long-term remission after one course of neoadjuvant chemotherapy with FLOT regimen in a patient with locally advanced gastric cancer.Case description. A 69-year-old patient presented to A. Tsyb Medical Radiological Research Centre with complaints of general weakness, moderate epigastric pain for 2 months. The examination revealed stage T3N0M0 IIA gastric cancer. The patient received one cycle of neoadjuvant chemotherapy with the FLOT regimen. Given the fact, that the patient developed massive bleeding from the tumor, it was decided to stop neoadjuvant treatment. Subtotal gastrectomy with D2 lymph node dissection was performed. Histological examination of the surgical specimen revealed pathological complete response (grade 1a according to the classification of K.Becker et al., 2003). The patient is alive with no signs of disease progression for more than 36 months after starting the treatment.Conclusion. This clinical case demonstrated personalized approach to the treatment of patients with locally advanced gastric cancer. Pathological complete response was achieved after one cycle of neoadjuvant chemotherapy.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">рак желудка</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">периоперационная химиотерапия flot</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">хирургическое лечение</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">гастрэктомия</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">лечебный патоморфоз</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">динамическое наблюдение</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">D. D. Kudriavtsev</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">V. N. Shitareva</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">E. S. Zhavoronkovа</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Сибирский онкологический журнал</subfield><subfield code="d">Russian Academy of Sciences, Tomsk National Research Medical Center, 2017</subfield><subfield code="g">21(2023), 6, Seite 164-169</subfield><subfield code="w">(DE-627)731335074</subfield><subfield code="w">(DE-600)2693095-X</subfield><subfield code="x">23123168</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:21</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:6</subfield><subfield code="g">pages:164-169</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.21294/1814-4861-2022-21-6-164-169</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/03836cccc4a54d439514afd374b1264b</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.siboncoj.ru/jour/article/view/2388</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1814-4861</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2312-3168</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">21</subfield><subfield code="j">2023</subfield><subfield code="e">6</subfield><subfield code="h">164-169</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	V. Yu. Skoropad
spellingShingle	V. Yu. Skoropad misc RC254-282 misc рак желудка misc периоперационная химиотерапия flot misc хирургическое лечение misc гастрэктомия misc лечебный патоморфоз misc динамическое наблюдение misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens Clinical case of pathological complete response of gastric cancer after one cycle of neoadjuvant chemotherapy with fot regimen
authorStr	V. Yu. Skoropad
ppnlink_with_tag_str_mv	@@773@@(DE-627)731335074
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RC254-282
illustrated	Not Illustrated
issn	23123168
topic_title	RC254-282 Clinical case of pathological complete response of gastric cancer after one cycle of neoadjuvant chemotherapy with fot regimen рак желудка периоперационная химиотерапия flot хирургическое лечение гастрэктомия лечебный патоморфоз динамическое наблюдение
topic	misc RC254-282 misc рак желудка misc периоперационная химиотерапия flot misc хирургическое лечение misc гастрэктомия misc лечебный патоморфоз misc динамическое наблюдение misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
topic_unstemmed	misc RC254-282 misc рак желудка misc периоперационная химиотерапия flot misc хирургическое лечение misc гастрэктомия misc лечебный патоморфоз misc динамическое наблюдение misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
topic_browse	misc RC254-282 misc рак желудка misc периоперационная химиотерапия flot misc хирургическое лечение misc гастрэктомия misc лечебный патоморфоз misc динамическое наблюдение misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Сибирский онкологический журнал
hierarchy_parent_id	731335074
hierarchy_top_title	Сибирский онкологический журнал
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)731335074 (DE-600)2693095-X
title	Clinical case of pathological complete response of gastric cancer after one cycle of neoadjuvant chemotherapy with fot regimen
ctrlnum	(DE-627)DOAJ088670007 (DE-599)DOAJ03836cccc4a54d439514afd374b1264b
title_full	Clinical case of pathological complete response of gastric cancer after one cycle of neoadjuvant chemotherapy with fot regimen
author_sort	V. Yu. Skoropad
journal	Сибирский онкологический журнал
journalStr	Сибирский онкологический журнал
callnumber-first-code	R
lang_code	rus
isOA_bool	true
recordtype	marc
publishDateSort	2023
contenttype_str_mv	txt
container_start_page	164
author_browse	V. Yu. Skoropad D. D. Kudriavtsev V. N. Shitareva E. S. Zhavoronkovа
container_volume	21
class	RC254-282
format_se	Elektronische Aufsätze
author-letter	V. Yu. Skoropad
doi_str_mv	10.21294/1814-4861-2022-21-6-164-169
author2-role	verfasserin
title_sort	clinical case of pathological complete response of gastric cancer after one cycle of neoadjuvant chemotherapy with fot regimen
callnumber	RC254-282
title_auth	Clinical case of pathological complete response of gastric cancer after one cycle of neoadjuvant chemotherapy with fot regimen
abstract	Background. Gastric cancer is the 5th most common cancer and the 3rd leading cause of cancer death globally. In Russia, gastric cancer is the 2-nd leading cause of death (10.7 %). Surgery in combination with perioperative/adjuvant chemotherapy is the standard treatment for locally advanced gastric cancer. Four cycles of neoadjuvant chemotherapy and 4 cycles of adjuvant chemotherapy with the FLOT regimen is the most widely used treatment modality. The basis for the widespread use of this chemotherapy regimen was the results of a large randomized FLOT4 trial, according to which the perioperative FLOT regimen showed greater efficacy compared to the ECF regimen.The aim of the study was to demonstrate the feasibility of achieving patholopgical complete response and long-term remission after one course of neoadjuvant chemotherapy with FLOT regimen in a patient with locally advanced gastric cancer.Case description. A 69-year-old patient presented to A. Tsyb Medical Radiological Research Centre with complaints of general weakness, moderate epigastric pain for 2 months. The examination revealed stage T3N0M0 IIA gastric cancer. The patient received one cycle of neoadjuvant chemotherapy with the FLOT regimen. Given the fact, that the patient developed massive bleeding from the tumor, it was decided to stop neoadjuvant treatment. Subtotal gastrectomy with D2 lymph node dissection was performed. Histological examination of the surgical specimen revealed pathological complete response (grade 1a according to the classification of K.Becker et al., 2003). The patient is alive with no signs of disease progression for more than 36 months after starting the treatment.Conclusion. This clinical case demonstrated personalized approach to the treatment of patients with locally advanced gastric cancer. Pathological complete response was achieved after one cycle of neoadjuvant chemotherapy.
abstractGer	Background. Gastric cancer is the 5th most common cancer and the 3rd leading cause of cancer death globally. In Russia, gastric cancer is the 2-nd leading cause of death (10.7 %). Surgery in combination with perioperative/adjuvant chemotherapy is the standard treatment for locally advanced gastric cancer. Four cycles of neoadjuvant chemotherapy and 4 cycles of adjuvant chemotherapy with the FLOT regimen is the most widely used treatment modality. The basis for the widespread use of this chemotherapy regimen was the results of a large randomized FLOT4 trial, according to which the perioperative FLOT regimen showed greater efficacy compared to the ECF regimen.The aim of the study was to demonstrate the feasibility of achieving patholopgical complete response and long-term remission after one course of neoadjuvant chemotherapy with FLOT regimen in a patient with locally advanced gastric cancer.Case description. A 69-year-old patient presented to A. Tsyb Medical Radiological Research Centre with complaints of general weakness, moderate epigastric pain for 2 months. The examination revealed stage T3N0M0 IIA gastric cancer. The patient received one cycle of neoadjuvant chemotherapy with the FLOT regimen. Given the fact, that the patient developed massive bleeding from the tumor, it was decided to stop neoadjuvant treatment. Subtotal gastrectomy with D2 lymph node dissection was performed. Histological examination of the surgical specimen revealed pathological complete response (grade 1a according to the classification of K.Becker et al., 2003). The patient is alive with no signs of disease progression for more than 36 months after starting the treatment.Conclusion. This clinical case demonstrated personalized approach to the treatment of patients with locally advanced gastric cancer. Pathological complete response was achieved after one cycle of neoadjuvant chemotherapy.
abstract_unstemmed	Background. Gastric cancer is the 5th most common cancer and the 3rd leading cause of cancer death globally. In Russia, gastric cancer is the 2-nd leading cause of death (10.7 %). Surgery in combination with perioperative/adjuvant chemotherapy is the standard treatment for locally advanced gastric cancer. Four cycles of neoadjuvant chemotherapy and 4 cycles of adjuvant chemotherapy with the FLOT regimen is the most widely used treatment modality. The basis for the widespread use of this chemotherapy regimen was the results of a large randomized FLOT4 trial, according to which the perioperative FLOT regimen showed greater efficacy compared to the ECF regimen.The aim of the study was to demonstrate the feasibility of achieving patholopgical complete response and long-term remission after one course of neoadjuvant chemotherapy with FLOT regimen in a patient with locally advanced gastric cancer.Case description. A 69-year-old patient presented to A. Tsyb Medical Radiological Research Centre with complaints of general weakness, moderate epigastric pain for 2 months. The examination revealed stage T3N0M0 IIA gastric cancer. The patient received one cycle of neoadjuvant chemotherapy with the FLOT regimen. Given the fact, that the patient developed massive bleeding from the tumor, it was decided to stop neoadjuvant treatment. Subtotal gastrectomy with D2 lymph node dissection was performed. Histological examination of the surgical specimen revealed pathological complete response (grade 1a according to the classification of K.Becker et al., 2003). The patient is alive with no signs of disease progression for more than 36 months after starting the treatment.Conclusion. This clinical case demonstrated personalized approach to the treatment of patients with locally advanced gastric cancer. Pathological complete response was achieved after one cycle of neoadjuvant chemotherapy.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	6
title_short	Clinical case of pathological complete response of gastric cancer after one cycle of neoadjuvant chemotherapy with fot regimen
url	https://doi.org/10.21294/1814-4861-2022-21-6-164-169 https://doaj.org/article/03836cccc4a54d439514afd374b1264b https://www.siboncoj.ru/jour/article/view/2388 https://doaj.org/toc/1814-4861 https://doaj.org/toc/2312-3168
remote_bool	true
author2	D. D. Kudriavtsev V. N. Shitareva E. S. Zhavoronkovа
author2Str	D. D. Kudriavtsev V. N. Shitareva E. S. Zhavoronkovа
ppnlink	731335074
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.21294/1814-4861-2022-21-6-164-169
callnumber-a	RC254-282
up_date	2024-07-03T18:55:45.128Z
_version_	1803585265473683456
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ088670007</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230410120511.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230410s2023 xx \|\|\|\|\|o 00\| \|\|rus c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.21294/1814-4861-2022-21-6-164-169</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ088670007</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ03836cccc4a54d439514afd374b1264b</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">V. Yu. Skoropad</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Clinical case of pathological complete response of gastric cancer after one cycle of neoadjuvant chemotherapy with fot regimen</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background. Gastric cancer is the 5th most common cancer and the 3rd leading cause of cancer death globally. In Russia, gastric cancer is the 2-nd leading cause of death (10.7 %). Surgery in combination with perioperative/adjuvant chemotherapy is the standard treatment for locally advanced gastric cancer. Four cycles of neoadjuvant chemotherapy and 4 cycles of adjuvant chemotherapy with the FLOT regimen is the most widely used treatment modality. The basis for the widespread use of this chemotherapy regimen was the results of a large randomized FLOT4 trial, according to which the perioperative FLOT regimen showed greater efficacy compared to the ECF regimen.The aim of the study was to demonstrate the feasibility of achieving patholopgical complete response and long-term remission after one course of neoadjuvant chemotherapy with FLOT regimen in a patient with locally advanced gastric cancer.Case description. A 69-year-old patient presented to A. Tsyb Medical Radiological Research Centre with complaints of general weakness, moderate epigastric pain for 2 months. The examination revealed stage T3N0M0 IIA gastric cancer. The patient received one cycle of neoadjuvant chemotherapy with the FLOT regimen. Given the fact, that the patient developed massive bleeding from the tumor, it was decided to stop neoadjuvant treatment. Subtotal gastrectomy with D2 lymph node dissection was performed. Histological examination of the surgical specimen revealed pathological complete response (grade 1a according to the classification of K.Becker et al., 2003). The patient is alive with no signs of disease progression for more than 36 months after starting the treatment.Conclusion. This clinical case demonstrated personalized approach to the treatment of patients with locally advanced gastric cancer. Pathological complete response was achieved after one cycle of neoadjuvant chemotherapy.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">рак желудка</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">периоперационная химиотерапия flot</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">хирургическое лечение</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">гастрэктомия</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">лечебный патоморфоз</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">динамическое наблюдение</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">D. D. Kudriavtsev</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">V. N. Shitareva</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">E. S. Zhavoronkovа</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Сибирский онкологический журнал</subfield><subfield code="d">Russian Academy of Sciences, Tomsk National Research Medical Center, 2017</subfield><subfield code="g">21(2023), 6, Seite 164-169</subfield><subfield code="w">(DE-627)731335074</subfield><subfield code="w">(DE-600)2693095-X</subfield><subfield code="x">23123168</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:21</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:6</subfield><subfield code="g">pages:164-169</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.21294/1814-4861-2022-21-6-164-169</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/03836cccc4a54d439514afd374b1264b</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.siboncoj.ru/jour/article/view/2388</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1814-4861</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2312-3168</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">21</subfield><subfield code="j">2023</subfield><subfield code="e">6</subfield><subfield code="h">164-169</subfield></datafield></record></collection>
score	7.4021854

Nicht das Richtige dabei?

Schreiben Sie uns!

Clinical case of pathological complete response of gastric cancer after one cycle of neoadjuvant chemotherapy with fot regimen

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?